Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis.

PURPOSE Concurrent chemoradiation therapy (CCRT) improves survival compared with sequential treatment for locally advanced non-small cell lung cancer, but it increases toxicity, particularly radiation esophagitis (RE). Validated predictors of RE for clinical use are lacking. We performed an individual-patient-data meta-analysis to determine factors predictive of clinically significant RE. METHODS AND MATERIALS After a systematic review of the literature, data were obtained on 1082 patients who underwent CCRT, including patients from Europe, North America, Asia, and Australia. Patients were randomly divided into training and validation sets (2/3 vs 1/3 of patients). Factors predictive of RE (grade≥2 and grade≥3) were assessed using logistic modeling, with the concordance statistic (c statistic) used to evaluate the performance of each model. RESULTS The median radiation therapy dose delivered was 65 Gy, and the median follow-up time was 2.1 years. Most patients (91%) received platinum-containing CCRT regimens. The development of RE was common, scored as grade 2 in 348 patients (32.2%), grade 3 in 185 (17.1%), and grade 4 in 10 (0.9%). There were no RE-related deaths. On univariable analysis using the training set, several baseline factors were statistically predictive of RE (P<.05), but only dosimetric factors had good discrimination scores (c>.60). On multivariable analysis, the esophageal volume receiving ≥60 Gy (V60) alone emerged as the best predictor of grade≥2 and grade≥3 RE, with good calibration and discrimination. Recursive partitioning identified 3 risk groups: low (V60<0.07%), intermediate (V60 0.07% to 16.99%), and high (V60≥17%). With use of the validation set, the predictive model performed inferiorly for the grade≥2 endpoint (c=.58) but performed well for the grade≥3 endpoint (c=.66). CONCLUSIONS Clinically significant RE is common, but life-threatening complications occur in <1% of patients. Although several factors are statistically predictive of RE, the V60 alone provides the best predictive ability. Efforts to reduce the V60 should be prioritized, with further research needed to identify and validate new predictive factors.

[1]  P. Lambin,et al.  Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  X. Sanz,et al.  Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy. , 2009, International journal of radiation oncology, biology, physics.

[3]  Jeffrey D Bradley,et al.  Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. , 2013, International journal of radiation oncology, biology, physics.

[4]  Di Yan,et al.  Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. , 2003, International journal of radiation oncology, biology, physics.

[5]  Kristin L. Sainani,et al.  Logistic Regression , 2014, PM & R : the journal of injury, function, and rehabilitation.

[6]  J. Deasy,et al.  Modeling the risk of radiation-induced acute esophagitis for combined Washington University and RTOG trial 93-11 lung cancer patients. , 2012, International journal of radiation oncology, biology, physics.

[7]  B. Yaremko,et al.  Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  Jan-Jakob Sonke,et al.  Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy. , 2012, International journal of radiation oncology, biology, physics.

[9]  E. Smit,et al.  Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  N. Hanna,et al.  Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. , 2010, International journal of radiation oncology, biology, physics.

[11]  G. Scagliotti,et al.  A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Tae Hyun Kim,et al.  Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy. , 2010, International journal of radiation oncology, biology, physics.

[13]  M. LaValley,et al.  Logistic Regression , 2008, Circulation.

[14]  Tae Hyun Kim,et al.  Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[15]  Joseph O Deasy,et al.  The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. , 2010, International journal of radiation oncology, biology, physics.

[16]  Joseph O. Deasy,et al.  Radiation dose-volume effects in the esophagus. , 2010, International journal of radiation oncology, biology, physics.

[17]  Nandita Mitra,et al.  Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  H. Thierens,et al.  Development of a multicomponent prediction model for acute esophagitis in lung cancer patients receiving chemoradiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[19]  Suresh Senan,et al.  European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. O'Rourke,et al.  Concurrent chemoradiotherapy in non-small cell lung cancer. , 2010, The Cochrane database of systematic reviews.